BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

747 related articles for article (PubMed ID: 23262793)

  • 1. Pharmacokinetic approach for dynamic breast MRI to indicate signal intensity time curves of benign and malignant lesions by using the tumor flow residence time.
    Renz DM; Diekmann F; Schmitzberger FF; Pietsch H; Fallenberg EM; Durmus T; Huppertz A; Böttcher J; Bick U; Hamm B; Lawaczeck R
    Invest Radiol; 2013 Feb; 48(2):69-78. PubMed ID: 23262793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
    Liang J; Sammet S; Yang X; Jia G; Takayama Y; Knopp MV
    Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linear Gadolinium-Based Contrast Agents Are Associated With Brain Gadolinium Retention in Healthy Rats.
    Robert P; Violas X; Grand S; Lehericy S; Idée JM; Ballet S; Corot C
    Invest Radiol; 2016 Feb; 51(2):73-82. PubMed ID: 26606549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast lesion detection and characterization at contrast-enhanced MR mammography: gadobenate dimeglumine versus gadopentetate dimeglumine.
    Pediconi F; Catalano C; Occhiato R; Venditti F; Fraioli F; Napoli A; Kirchin MA; Passariello R
    Radiology; 2005 Oct; 237(1):45-56. PubMed ID: 16126926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Quantitative Lung Perfusion Imaging Using the Dual-Bolus Approach: Comparison of 3 Contrast Agents and Recommendation of Feasible Doses.
    Veldhoen S; Oechsner M; Fischer A; Weng AM; Kunz AS; Bley TA; Köstler H; Ritter CO
    Invest Radiol; 2016 Mar; 51(3):186-93. PubMed ID: 26606550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pelvic lesions in patients with treated cervical carcinoma: efficacy of pharmacokinetic analysis of dynamic MR images in distinguishing recurrent tumors from benign conditions.
    Hawighorst H; Knapstein PG; Schaeffer U; Knopp MV; Brix G; Hoffmann U; Zuna I; Essig M; van Kaick G
    AJR Am J Roentgenol; 1996 Feb; 166(2):401-8. PubMed ID: 8553955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revisiting the Pharmacokinetic Profiles of Gadolinium-Based Contrast Agents: Differences in Long-Term Biodistribution and Excretion.
    Lancelot E
    Invest Radiol; 2016 Nov; 51(11):691-700. PubMed ID: 27175546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neural network approach to the segmentation and classification of dynamic magnetic resonance images of the breast: comparison with empiric and quantitative kinetic parameters.
    Szabó BK; Aspelin P; Wiberg MK
    Acad Radiol; 2004 Dec; 11(12):1344-54. PubMed ID: 15596372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DCE-MR imaging of orbital lesions: diagnostic performance of the tumor flow residence time τ calculated by a multi-compartmental pharmacokinetic tumor model based on individual factors.
    Erb-Eigner K; Asbach P; Ro SR; Haas M; Bertelmann E; Pietsch H; Schwenke C; Taupitz M; Denecke T; Hamm B; Lawaczeck R
    Acta Radiol; 2019 May; 60(5):643-652. PubMed ID: 30114927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraindividual quantitative and qualitative comparison of gadopentetate dimeglumine and gadobutrol in time-resolved contrast-enhanced 4-dimensional magnetic resonance angiography in minipigs.
    Hadizadeh DR; Jost G; Pietsch H; Weibrecht M; Perkuhn M; Boschewitz JM; Keil VC; Träber F; Kukuk GM; Schild HH; Willinek WA
    Invest Radiol; 2014 Jul; 49(7):457-64. PubMed ID: 24598442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification and Assessment of the Chemical Form of Residual Gadolinium in the Brain After Repeated Administration of Gadolinium-Based Contrast Agents: Comparative Study in Rats.
    Frenzel T; Apte C; Jost G; Schöckel L; Lohrke J; Pietsch H
    Invest Radiol; 2017 Jul; 52(7):396-404. PubMed ID: 28125438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gadolinium Retention, Brain T1 Hyperintensity, and Endogenous Metals: A Comparative Study of Macrocyclic Versus Linear Gadolinium Chelates in Renally Sensitized Rats.
    Rasschaert M; Emerit A; Fretellier N; Factor C; Robert P; Idée JM; Corot C
    Invest Radiol; 2018 Jun; 53(6):328-337. PubMed ID: 29329151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T.
    Attenberger UI; Runge VM; Jackson CB; Baumann S; Birkemeier K; Michaely HJ; Schoenberg SO; Reiser MF; Wintersperger BJ
    Invest Radiol; 2009 May; 44(5):251-6. PubMed ID: 19550376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Washout of mass-like benign breast lesions at dynamic magnetic resonance imaging.
    Tannaphai P; Trimboli RM; Carbonaro LA; Viganò S; Di Leo G; Sardanelli F
    J Comput Assist Tomogr; 2012; 36(3):301-5. PubMed ID: 22592612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of gadobutrol, a macrocyclic, nonionic gadolinium chelate in a brain glioma model: comparison with gadoterate meglumine and gadopentetate dimeglumine at 1.5 T, combined with an assessment of field strength dependence, specifically 1.5 versus 3 T.
    Attenberger UI; Runge VM; Morelli JN; Williams J; Jackson CB; Michaely HJ
    J Magn Reson Imaging; 2010 Mar; 31(3):549-55. PubMed ID: 20187196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine.
    Knopp MV; Bourne MW; Sardanelli F; Wasser MN; Bonomo L; Boetes C; Müller-Schimpfle M; Hall-Craggs MA; Hamm B; Orlacchio A; Bartolozzi C; Kessler M; Fischer U; Schneider G; Oudkerk M; Teh WL; Gehl HB; Salerio I; Pirovano G; La Noce A; Kirchin MA; Spinazzi A
    AJR Am J Roentgenol; 2003 Sep; 181(3):663-76. PubMed ID: 12933457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic contrast-enhanced magnetic resonance imaging of the breast combined with pharmacokinetic analysis of gadolinium-DTPA uptake in the diagnosis of local recurrence of early stage breast carcinoma.
    Mussurakis S; Buckley DL; Bowsley SJ; Carleton PJ; Fox JN; Turnbull LW; Horsman A
    Invest Radiol; 1995 Nov; 30(11):650-62. PubMed ID: 8557506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-T dynamic contrast-enhanced MRI of the breast: pharmacokinetic parameters versus conventional kinetic curve analysis.
    El Khouli RH; Macura KJ; Kamel IR; Jacobs MA; Bluemke DA
    AJR Am J Roentgenol; 2011 Dec; 197(6):1498-505. PubMed ID: 22109308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of gadobenate dimeglumine in isolated perfused rat liver: MR imaging evaluation.
    Pastor CM; Planchamp C; Pochon S; Lorusso V; Montet X; Mayer J; Terrier F; Vallee JP
    Radiology; 2003 Oct; 229(1):119-25. PubMed ID: 12944603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrast-enhanced MR mammography: improved lesion detection and differentiation with gadobenate dimeglumine.
    Pediconi F; Catalano C; Padula S; Roselli A; Dominelli V; Cagioli S; Kirchin MA; Pirovano G; Passariello R
    AJR Am J Roentgenol; 2008 Nov; 191(5):1339-46. PubMed ID: 18941066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.